Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth A Pilling

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Drug Discovery Today|August 4, 2024
Multidisciplinary considerations for implementing Bayesian borrowing in basket trialsKristine R Broglio, Jenny E Blau, Elizabeth A Pilling, et al.
Pharmaceutical Statistics|July 5, 2023
Defining estimands for efficacy assessment in single arm phase 1b or phase 2 clinical trials in oncology early developmentStefan Englert, François Mercier, Elizabeth A Pilling, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 31, 2022
Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid TumorsEmerson A Lim, Johanna C Bendell, Gerald S Falchook, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Drug Discovery Today|August 4, 2024
Multidisciplinary considerations for implementing Bayesian borrowing in basket trialsKristine R Broglio, Jenny E Blau, Elizabeth A Pilling, et al.
Pharmaceutical Statistics|July 5, 2023
Defining estimands for efficacy assessment in single arm phase 1b or phase 2 clinical trials in oncology early developmentStefan Englert, François Mercier, Elizabeth A Pilling, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 31, 2022
Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid TumorsEmerson A Lim, Johanna C Bendell, Gerald S Falchook, et al.
Pageof 1